Gritstone bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Gritstone bio hat ein Gesamteigenkapital von $22.2M und eine Gesamtverschuldung von $40.5M, was einen Verschuldungsgrad von 182.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $142.5M bzw. $120.4M.

Wichtige Informationen

182.5%

Verhältnis von Schulden zu Eigenkapital

US$40.51m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$55.71m
Eigenkapital	US$22.19m
Gesamtverbindlichkeiten	US$120.35m
Gesamtvermögen	US$142.54m

Jüngste Berichte zur Finanzlage

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Jul 07

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Mar 05

Recent updates

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Jun 11

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Apr 07

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Aug 14

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GRTS.QDie kurzfristigen Aktiva des Unternehmens ($60.7M) übersteigen seine kurzfristigen Passiva ($23.9M).

Langfristige Verbindlichkeiten: GRTS.QDie kurzfristigen Vermögenswerte des Unternehmens ($60.7M) decken seine langfristigen Verbindlichkeiten ($96.5M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GRTS.Q über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: GRTS.QDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 182.5% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: GRTS.Q hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: GRTS.Q hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 13.8% pro Jahr abnimmt

Gritstone bio Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate

Recent updates

Motion for Asset Sale Filed by Gritstone bio, Inc.

Gritstone bio, Inc.(OTCPK:GRTS.Q) dropped from NASDAQ Composite Index

New major risk - Revenue and earnings growth

Gritstone bio Receives Delisting Notice from Nasdaq Due to Chapter 11 Case and it Does Not Intend to Appeal the Determination

New major risk - Market cap size

New major risk - Share price stability

Gritstone Bio Announces Interim Phase 2 Data for Granite Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

Consensus revenue estimates decrease by 60%, EPS upgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

Gritstone Bio, Inc. Receives Non-Compliance Notice Regarding Minimum Bid Price Requirement

We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation

Price target decreased by 16% to US$4.33

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

Gritstone bio, Inc. to Report Q1, 2024 Results on May 09, 2024

Gritstone bio, Inc., Annual General Meeting, Jun 17, 2024

Gritstone Bio, Inc. Announces Board Changes

Consensus revenue estimates decrease by 17%, EPS upgraded

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform (SLATE)

New minor risk - Market cap size

Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering

Gritstone bio, Inc. has completed a Follow-on Equity Offering in the amount of $32.5 million.

Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA (ctDNA) Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite

Consensus revenue estimates decrease by 37%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 12% to US$8.80

Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial

Consensus revenue estimates fall by 40%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna (Samrna) Vaccine Candidates Against Covid-19 (Part of the Company’s Coral Program) at IDWeek 2023

Price target increased by 20% to US$10.34

Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%

Price target increased by 20% to US$10.34

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Financial position

Consensus revenue estimates fall by 53%

Price target decreased by 14% to US$8.60

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Gritstone bio, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.75

Gritstone bio, Inc. Announces Updated Overall Survival Results from Granite Phase 1/2 Study and Poster At Sitc 2022

Price target decreased to US$10.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Gritstone bio, Inc. announced that it expects to receive $44.999991 million in funding from Redmile Group, LLC, Gilead Sciences, Inc., The Invus Group, LLC, Hercules Capital, Inc. and other investors

Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst

Gritstone bio, Inc. Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated with KRAS-Directed Immunotherapy at ESMO 2022

Gritstone reaches six-month high on publication of data for cancer vaccine

Gritstone bio, Inc. Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors

Consensus revenue estimates increase by 14%

Gritstone Appoints Dr. Lawrence “Larry” Corey to Its Board of Directors, Effective from August 12, 2022

Price target increased to US$16.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio announces $80M credit facility

Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?

Gritstone bio: Potential To Advance Colorectal Cancer Treatment

Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from Russell 2500 Index

Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation

Gritstone Announces Results from Preclinical Study of Its Self-Amplifying Mrna (Samrna) Vaccine Against Sars-Cov-2 Published in Nature Communications

Gritstone Bio, Inc. Announces Updated Overall Survival Results in Advanced Colorectal Cancer Patients from Phase 1/2 Study of Granite and Trial in Progress Poster At Asco

Price target increased to US$16.00

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Gritstone bio, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$14.67